DXNVX Signs Genome Analysis Service Supply Agreement with Mongolian Biomedical Company RCC

DXVX announced on the 12th that it has signed a supply contract with Regenerative Cell Center LLC (hereinafter ‘RCC’), a major hospital partner in Mongolia, to provide its genome analysis service ‘GenomeCheck’ to the Mongolian market.

RCC is a biomedical company that partners with Mongolia’s infertility and reproductive clinic center RMC IVF (In Vitro Fertilization) Center, providing genome analysis services such as NIPT (Non-Invasive Prenatal Testing) and PGT (Preimplantation Genetic Testing), as well as local marketing. The partner infertility center in Mongolia is a local hospital specializing in infertility patients and is leading the domestic distribution of genome analysis services.

In Mongolia, the number of pregnancies among women aged 35 and older is increasing, and awareness of genome analysis services for maternal and fetal health management is rapidly growing, so the market is expected to expand in the future.

GenomeCheck enables non-invasive prenatal genetic testing for mothers and fetuses, as well as newborn genetic testing. DXVX evaluated that this contract was achieved based on the service’s excellence, including the number of diseases that can be tested, high accuracy, and short testing periods. DXVX is currently reviewing additional contracts with three biomedical companies in Malaysia, including MGRC, and is expected to expand its market from Northeast Asia to Southeast Asia, securing a leading position in the global medical market starting with this supply contract for the Mongolian market.

Dr. Odkhuu Enkhtaivan, CEO of RCC and RMC and an obstetrics and gynecology specialist, said, “The cooperation between the two companies is a very exciting opportunity,” adding, “It is very encouraging that this collaboration has made RCC and DXVX key partners to each other.”

DXVX CEO Kwon Kyu-chan stated, “Starting with this supply contract for the Mongolian market, we will strive to expand the genome analysis service, which has been recognized for its technology and safety by domestic medical professionals, to the global market,” and added, “We are also accelerating the global supply of microbiome-based healthcare products, and plan to target the healthcare market starting with products focused on mothers and fetuses.”

This content was produced with the assistance of AI translation services.